



Advances in the Development of New Drugs and Treatment Targets for Brain Cancers

Guest Editors:

Dr. Luis Ibarra

**Dr. Laura Natalia Milla
Sanabria**

Dr. Nuria Arias-Ramos

Deadline for manuscript
submissions:

closed (20 December 2023)

Message from the Guest Editors

Brain cancers represent a significant challenge for current oncology and drug development. Despite being rare in the general population, malignant brain tumors can occur in both adults and children. Standard treatment regimens consist of maximal surgical resection followed by radiotherapy and chemotherapy. However, the main issue is they are ‘protected’ by the most impermeable biological barrier—the blood-brain barrier. The 2021 edition of the WHO Classification of Tumors of the Central Nervous System emphasizes the advanced role of molecular diagnostics in the identification of molecular biomarkers, in addition to histologic features in the classification of CNS tumors to improve the new treatments. In recent decades, potent chemotherapeutic agents, oligonucleotides and antibodies for targeted therapy, multifunctional nanomedicines, immunotherapies and cell-based therapies have been developed and proposed to overcome most of the issues that arise due to the location of brain tumors and their biological barriers. This SI invites papers covering new therapeutic strategies and target drugs, exploring the importance of brain tumors at cellular and molecular levels.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Stephen D. Meriney

Department of Neuroscience,
University of Pittsburgh,
Pittsburgh, PA 15260, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYINDEX, PsycInfo, CAPlus / SciFinder, and other databases.

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.2 days after submission; acceptance to publication is undertaken in 1.9 days (median values for papers published in this journal in the first half of 2025).

Contact Us

Brain Sciences Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/brainsci
brainsci@mdpi.com
[X@BrainSci_MDPI](https://twitter.com/BrainSci_MDPI)